Overexpression of MYC and EZH2 cooperates to epigenetically silence MST1 expression

References

• Harvey K, Tapon N. The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network. Nat Rev Cancer 2007; 7:182 - 91; http://dx.doi.org/10.1038/nrc2070; PMID: 17318211
   PubMed Web of Science ®Google Scholar
• Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, Wang Y, Halder G, Finegold MJ, Lee JS, et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A 2010; 107:1437 - 42; http://dx.doi.org/10.1073/pnas.0911427107; PMID: 20080689
   PubMed Web of Science ®Google Scholar
• Song H, Mak KK, Topol L, Yun K, Hu J, Garrett L, Chen Y, Park O, Chang J, Simpson RM, et al. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci U S A 2010; 107:1431 - 6; http://dx.doi.org/10.1073/pnas.0911409107; PMID: 20080598
   PubMed Web of Science ®Google Scholar
• Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, Lauwers GY, Thasler W, Lee JT, Avruch J, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 2009; 16:425 - 38; http://dx.doi.org/10.1016/j.ccr.2009.09.026; PMID: 19878874
   PubMed Web of Science ®Google Scholar
• Zhou D, Zhang Y, Wu H, Barry E, Yin Y, Lawrence E, Dawson D, Willis JE, Markowitz SD, Camargo FD, et al. Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc Natl Acad Sci U S A 2011; 108:E1312 - 20; http://dx.doi.org/10.1073/pnas.1110428108; PMID: 22042863
   PubMed Web of Science ®Google Scholar
• Qiao M, Wang Y, Xu X, Lu J, Dong Y, Tao W, Stein J, Stein GS, Iglehart JD, Shi Q, et al. Mst1 is an interacting protein that mediates PHLPPs’ induced apoptosis. Mol Cell 2010; 38:512 - 23; http://dx.doi.org/10.1016/j.molcel.2010.03.017; PMID: 20513427
   PubMed Web of Science ®Google Scholar
• Steinmann K, Sandner A, Schagdarsurengin U, Dammann RH. Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma. Oncol Rep 2009; 22:1519 - 26; PMID: 19885608
   PubMed Web of Science ®Google Scholar
• Minoo P, Zlobec I, Baker K, Tornillo L, Terracciano L, Jass JR, Lugli A. Prognostic significance of mammalian sterile20-like kinase 1 in colorectal cancer. Mod Pathol 2007; 20:331 - 8; http://dx.doi.org/10.1038/modpathol.3800740; PMID: 17277767
   PubMed Web of Science ®Google Scholar
• Lin X, Cai F, Li X, Kong X, Xu C, Zuo X, Yang Q. Prognostic significance of mammalian sterile 20-like kinase 1 in breast cancer. Tumour Biol 2013; 34:3239 - 43; http://dx.doi.org/10.1007/s13277-013-0895-8; PMID: 23737290
   PubMed Web of Science ®Google Scholar
• Cinar B, Fang PK, Lutchman M, Di Vizio D, Adam RM, Pavlova N, Rubin MA, Yelick PC, Freeman MR. The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1. EMBO J 2007; 26:4523 - 34; http://dx.doi.org/10.1038/sj.emboj.7601872; PMID: 17932490
   PubMed Web of Science ®Google Scholar
• Cinar B, Collak FK, Lopez D, Akgul S, Mukhopadhyay NK, Kilicarslan M, Gioeli DG, Freeman MR. MST1 is a multifunctional caspase-independent inhibitor of androgenic signaling. Cancer Res 2011; 71:4303 - 13; http://dx.doi.org/10.1158/0008-5472.CAN-10-4532; PMID: 21512132
   PubMed Web of Science ®Google Scholar
• Collak FK, Yagiz K, Luthringer DJ, Erkaya B, Cinar B. Threonine-120 phosphorylation regulated by phosphoinositide-3-kinase/Akt and mammalian target of rapamycin pathway signaling limits the antitumor activity of mammalian sterile 20-like kinase 1. J Biol Chem 2012; 287:23698 - 709; http://dx.doi.org/10.1074/jbc.M112.358713; PMID: 22619175
   PubMed Web of Science ®Google Scholar
• Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 1998; 153:141 - 8; http://dx.doi.org/10.1016/S0002-9440(10)65554-X; PMID: 9665474
   PubMed Web of Science ®Google Scholar
• Visakorpi T, Kallioniemi AH, Syvänen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi OP. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995; 55:342 - 7; PMID: 7529134
   PubMed Web of Science ®Google Scholar
• Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM. MYC and Prostate Cancer. Genes Cancer 2010; 1:617 - 28; http://dx.doi.org/10.1177/1947601910379132; PMID: 21779461
   PubMedGoogle Scholar
• Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV, Sawyers CL. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003; 4:223 - 38; http://dx.doi.org/10.1016/S1535-6108(03)00197-1; PMID: 14522256
   PubMed Web of Science ®Google Scholar
• Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS, Zhang Y. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002; 298:1039 - 43; http://dx.doi.org/10.1126/science.1076997; PMID: 12351676
   PubMed Web of Science ®Google Scholar
• Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419:624 - 9; http://dx.doi.org/10.1038/nature01075; PMID: 12374981
   PubMed Web of Science ®Google Scholar
• Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 2012; 338:1465 - 9; http://dx.doi.org/10.1126/science.1227604; PMID: 23239736
   PubMed Web of Science ®Google Scholar
• Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, Eden E, Yakhini Z, Ben-Shushan E, Reubinoff BE, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007; 39:232 - 6; http://dx.doi.org/10.1038/ng1950; PMID: 17200670
   PubMed Web of Science ®Google Scholar
• Patra SK, Patra A, Zhao H, Dahiya R. DNA methyltransferase and demethylase in human prostate cancer. Mol Carcinog 2002; 33:163 - 71; http://dx.doi.org/10.1002/mc.10033; PMID: 11870882
   PubMed Web of Science ®Google Scholar
• De Carvalho DD, Sharma S, You JS, Su SF, Taberlay PC, Kelly TK, Yang X, Liang G, Jones PA. DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell 2012; 21:655 - 67; http://dx.doi.org/10.1016/j.ccr.2012.03.045; PMID: 22624715
   PubMed Web of Science ®Google Scholar
• Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo AM. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget 2011; 2:669 - 83; PMID: 21941025
   PubMed Web of Science ®Google Scholar
• Kaur M, Cole MD. MYC acts via the PTEN tumor suppressor to elicit autoregulation and genome-wide gene repression by activation of the Ezh2 methyltransferase. Cancer Res 2013; 73:695 - 705; http://dx.doi.org/10.1158/0008-5472.CAN-12-2522; PMID: 23135913
   PubMed Web of Science ®Google Scholar
• Brenner C, Deplus R, Didelot C, Loriot A, Viré E, De Smet C, Gutierrez A, Danovi D, Bernard D, Boon T, et al. Myc represses transcription through recruitment of DNA methyltransferase corepressor. EMBO J 2005; 24:336 - 46; http://dx.doi.org/10.1038/sj.emboj.7600509; PMID: 15616584
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R, Zhang Y, Chan JC, Fu K, Marquez VE, et al. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell 2012; 22:506 - 23; http://dx.doi.org/10.1016/j.ccr.2012.09.003; PMID: 23079660
   PubMed Web of Science ®Google Scholar
• Seidel C, Schagdarsurengin U, Blümke K, Würl P, Pfeifer GP, Hauptmann S, Taubert H, Dammann R. Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol Carcinog 2007; 46:865 - 71; http://dx.doi.org/10.1002/mc.20317; PMID: 17538946
   PubMed Web of Science ®Google Scholar
• Bhat KP, Salazar KL, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F, James JD, Gumin J, Diefes KL, Kim SH, et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev 2011; 25:2594 - 609; http://dx.doi.org/10.1101/gad.176800.111; PMID: 22190458
   PubMed Web of Science ®Google Scholar
• Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET, Yu Q. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007; 21:1050 - 63; http://dx.doi.org/10.1101/gad.1524107; PMID: 17437993
   PubMed Web of Science ®Google Scholar
• McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A 3rd, Diaz E, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012; 492:108 - 12; http://dx.doi.org/10.1038/nature11606; PMID: 23051747
   PubMed Web of Science ®Google Scholar
• Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, Petrelli NJ, Dunn SP, Krueger LJ. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 2007; 67:9762 - 70; http://dx.doi.org/10.1158/0008-5472.CAN-07-2462; PMID: 17942906
   PubMed Web of Science ®Google Scholar
• Huang MJ, Cheng YC, Liu CR, Lin S, Liu HE. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol 2006; 34:1480 - 9; http://dx.doi.org/10.1016/j.exphem.2006.06.019; PMID: 17046567
   PubMed Web of Science ®Google Scholar
• Yin X, Giap C, Lazo JS, Prochownik EV. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 2003; 22:6151 - 9; http://dx.doi.org/10.1038/sj.onc.1206641; PMID: 13679853
   PubMed Web of Science ®Google Scholar
• Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146:904 - 17; http://dx.doi.org/10.1016/j.cell.2011.08.017; PMID: 21889194
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et al. Selective inhibition of BET bromodomains. Nature 2010; 468:1067 - 73; http://dx.doi.org/10.1038/nature09504; PMID: 20871596
   PubMed Web of Science ®Google Scholar
• Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF, Möller P, Stilgenbauer S, Pollack JR, Wirth T. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008; 112:4202 - 12; http://dx.doi.org/10.1182/blood-2008-03-147645; PMID: 18713946
   PubMed Web of Science ®Google Scholar
• Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, Chen YC, Peng Y, Yao KT, Kung HF, et al. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 2011; 71:225 - 33; http://dx.doi.org/10.1158/0008-5472.CAN-10-1850; PMID: 21199804
   PubMed Web of Science ®Google Scholar
• Viré E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden JM, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006; 439:871 - 4; http://dx.doi.org/10.1038/nature04431; PMID: 16357870
   PubMed Web of Science ®Google Scholar
• Gao L, Schwartzman J, Gibbs A, Lisac R, Kleinschmidt R, Wilmot B, Bottomly D, Coleman I, Nelson P, McWeeney S, et al. Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation. PLoS One 2013; 8:e63563; http://dx.doi.org/10.1371/journal.pone.0063563; PMID: 23704919
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay NK, Kim J, You S, Morello M, Hager MH, Huang WC, et al. Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2. Oncogene 2013; PMID: 23893242
   PubMed Web of Science ®Google Scholar
• Dang CV. MYC on the path to cancer. Cell 2012; 149:22 - 35; http://dx.doi.org/10.1016/j.cell.2012.03.003; PMID: 22464321
   PubMed Web of Science ®Google Scholar
• Civenni G, Malek A, Albino D, Garcia-Escudero R, Napoli S, Di Marco S, Pinton S, Sarti M, Carbone GM, Catapano CV. RNAi-mediated silencing of Myc transcription inhibits stem-like cell maintenance and tumorigenicity in prostate cancer. Cancer Res 2013; 73:6816 - 27; http://dx.doi.org/10.1158/0008-5472.CAN-13-0615; PMID: 24063893
   PubMed Web of Science ®Google Scholar
• Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, Chevalier B, Johnstone SE, Cole MF, Isono K, et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 2006; 125:301 - 13; http://dx.doi.org/10.1016/j.cell.2006.02.043; PMID: 16630818
   PubMed Web of Science ®Google Scholar
• Lian I, Kim J, Okazawa H, Zhao J, Zhao B, Yu J, Chinnaiyan A, Israel MA, Goldstein LS, Abujarour R, et al. The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes Dev 2010; 24:1106 - 18; http://dx.doi.org/10.1101/gad.1903310; PMID: 20516196
   PubMed Web of Science ®Google Scholar
• Gartel AL, Shchors K. Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes. Exp Cell Res 2003; 283:17 - 21; http://dx.doi.org/10.1016/S0014-4827(02)00020-4; PMID: 12565816
   PubMed Web of Science ®Google Scholar